摘要
他汀类药物有利于改善慢性肾损伤患者的心脑血管预后,但其副作用较大。血脂康作为中成药,其活性成分为洛伐他汀等多种降脂药物,安全性可靠,为了探讨血脂康在慢性肾脏病患者中与阿托伐他汀的疗效,研究分为血脂康组、阿托伐他汀组、安慰剂组,测定脂代谢、肾功能电解质、尿蛋白等指标。两种药物均可升高血总二氧化碳的表达,对维持酸碱平衡发挥了积极作用,且血脂康组效果更明显。血脂康及阿托伐他汀均可以改善慢性肾脏病患者的血脂水平,且血脂康对于酸碱平衡更有帮助。
Research objective:Statins are beneficial for improving the cardiovascular and cerebrovascular prognosis in patients with chronic kidney injury,but their side effects are significant.Xuezhikang,as a traditional Chinese patent medicines and simple preparations,its active ingredient is lovastatin and other lipid-lowering drugs,which is safe.This study is to explore the efficacy of Xuezhikang and atorvastatin in patients with chronic kidney disease.Method:The study was divided into Xuezhikang group,atorvastatin group,and placebo group.Indicators such as lipid metabolism,renal function electrolytes,and urinary protein were measured.Result:Both drugs can increase the expression of total blood carbon dioxide,playing a positive role in maintaining acid-base balance,and the effect of the Xuezhikang group is more significant.Conclusion:Both Xuezhikang and atorvastatin can improve blood lipid levels in patients with chronic kidney disease,and Xuezhikang is more helpful for acid-base balance.
作者
孙冬
邹小琴
Sun Dong;Zou Xiaoqin(Affiliated Hospital of Suzhou,Nanjing Medical University,Suzhou City,Jiangsu Province 215008)
出处
《黄河科技学院学报》
2024年第8期7-11,共5页
Journal of Huanghe S&T College
基金
国家自然科学基金项目(81670634)
苏州市民生科技指导性项目(SYSD2020130)。
关键词
血脂康
阿托伐他汀
慢性肾脏病
xuezhikang
atorvastatin
chronic kidney disease